Skip to main content

Advertisement

Table 2 Associations of KRAS codons 12 and 13, and BRAF mutation status with clinicopathological and molecular characteristics

From: Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study

  KRAS wild-type Codon 12-mutated Codon 13-mutated p value BRAF wild-type BRAF-mutated p value
  334 (63.7) a 156 (29.8) a 34 (6.5) a   446 (85.1) a 78 (14.9) a  
Age        
 Mean, median 70.5, 71.4 70.9, 71.4 68.5, 69.6 0.297b 70.2, 70.8 72.0, 73.1 0.017b
 Range 51.5–85.6 50.9–84.0 49.8–83.7 49.8–86.6 51.5–84.3
Sex        
 Female 177 (53.0) 83 (53.2) 18 (52.9) 0.999 227 (50.9) 50 (64.1) 0.031
 Male 157 (47.0) 73 (46.8) 16 (47.1) 219 (49.1) 28 (35.9)
Tumour location        
 Proximal 101 (30.4) 54 (34.6) 10 (29.4) 0.058 106 (23.8) 59 (77.6) <0.001
 Transverse 18 (5.4) 0 (0) 3 (8.8) 11 (2.5) 10 (13.2)
 Descending 15 (4.5) 12 (7.7) 1 (2.9) 24 (5.4) 4 (5.3)
 Sigmoid 66 (19.9) 38 (24.4) 7 (20.6) 110 (24.7) 1 (1.3)
 Rectum 132 (39.8) 52 (33.3) 13 (38.2) 195 (43.7) 2 (2.6)
 Missing 2 - - 0 2
T stage        
 1 32 (10.0) 9 (6.0) 4 (13.3) 0.291 42 (9.9) 3 (4.1) 0.001
 2 38 (11.9) 18 (11.9) 2 (6.7) 52 (12.2) 6 (8.1)
 3 201 (63.0) 104 (68.9) 16 (53.3) 278 (65.3) 43 (58.1)
 4 48 (15.0) 20 (13.2) 8 (26.7) 54 (12.7) 22 (29.7)
 Missing 15 5 4 20 4
N stage        
 0 180 (59.6) 84 (57.9) 15 (51.7) 0.710 241 (59.7) 37 (51.4) 0.353
 1 69 (22.8) 39 (26.9) 7 (24.1) 97 (24.0) 19 (26.4)
 2 53 (17.5) 22 (15.2) 7 (24.1) 66 (16.3) 16 (22.2)
 Missing 32 12 5 42 6
M stage        
 0 275 (84.1) 128 (82.6) 22 (64.7) 0.018 366 (83.0) 59 (78.7) 0.363
 1 52 (15.9) 27 (17.4) 12 (35.3) 75 (17.0) 16 (21.3)
 Missing 17 1 - 5 3
Differentiation grade        
 High 20 (6.2) 11 (7.1) 0 (0) 0.088 25 (5.7) 5 (6.8) <0.001
 Intermediate 222 (68.7) 121 (77.6) 26 (76.5) 340 (77.4) 30 (40.5)
 Low 81 (25.1) 24 (15.4) 8 (23.5) 74 (16.9) 39 (52.7)
 Missing 11 - - 7 4
Vascular invasion        
 No 95 (51.1) 45 (47.4) 7 ( 38.9) 0.561 125 (49.4) 21 (46.7) 0.735
 Yes 91 (48.9) 50 (52.6) 11 (61.1) 128 (50.6) 24 (53.3)
 Missing 148 61 16 193 33
Tumour type        
 Non-mucinous 269 (82.0) 114 (73.5) 28 (84.8) 0.073 360 (81.8) 50 (65.8) 0.001
 Mucinous 59 (18.0) 41 (26.5) 5 (15.2) 80 (18.2) 26 (34.2)
 Missing 6 1 1 6 2
MSI screening status        
 MSS 245 (79.3) 137 (96.5) 31 (93.9) <0.001 384 (93.2) 29 (40.3) <0.001
 MSI 64 (20.7) 5 (3.5) 2 (6.1) 28 (6.8) 43 (59.7)
 Missing 25 14 1 24 6
Beta-catenin grades        
 0–1 94 (29.7) 37 (25.0) 13 (38.2) 0.470 99 (23.4) 45 (59.2) <0.001
 2–3 108 (34.1) 48 (32.4) 9 (26.5) 138 (32.6) 26 (34.2)
 4–5 115 (36.3) 63 (42.6) 12 (35.3) 186 (44.0) 5 (6.6)
 Missing 17 8 - 23 2
p53 status        
 Negative 169 (53.1) 77 (51.3) 12 (37.5) 0.240 202 (47.6) 57 (75.0) <0.001
 Positive 149 (46.9) 73 (48.7) 20 (62.5) 222 (52.4) 19 (25.0)
 Missing 16 6 2 22 2
p21 Expression        
 Negative 43 (13.7) 22 (14.9) 5 (15.2) 0.931 63 (15.0) 7 (9.2) 0.180
 Positive 271 (86.3) 126 (85.1) 28 (84.8) 356 (85.0) 69 (90.8)
 Missing 20 8 1 27 2
p27 Expression        
 Negative 58 (18.4) 15 (10.1) 9 (27.3) 0.018 51 (12.1) 31 (40.8) <0 001
 Positive 258 (81.6) 134 (89.9) 24 (72.7) 371 (87.9) 45 (59.2)
 Missing 18 7 1 24 2
Cyclin D1 expression        
 Negative 63 (20.0) 23 (15.4) 10 (30.3) 0.129 90 (21.4) 5 (6.6) 0.003
 Positive 252 (80.0) 126 (84.6) 23 (69.7) 331 (78.6) 71 (93.4)
 Missing 19 7 1   25 2  
  1. a n (%); bKruskal-Wallis or Mann–Whitney U test. MSI microsatellite unstable, MSS microsatellite stable. One case with mutual codons 12 and 13 mutation was excluded from the analyses related to KRAS mutational status.